Life Sciences insights
33 results found
From $100,000 to $2 Million a Month: What AI at Scale Really Costs
WWT CFO and Chief Data Officer Tom Strunk and CIO Kevin Dana explain how organizational leaders can create AI cost visibility, govern variable consumption and connect rapidly growing token usage to measurable business outcomes.
Pharma's AI Infrastructure Imperative
How pharmaceutical and other life sciences organizations can build GPU infrastructure that matches the scale of their AI ambition.
Eli Lilly & Company Chief AI Officer on Why Lilly Bet Big on On-Prem AI
Eli Lilly & Company Chief AI Officer Thomas Fuchs explains why the pharma giant built its own on-prem AI supercomputer, LillyPod, instead of solely relying on the cloud. Fuchs, who has built machine learning infrastructure since long before AI was mainstream, argues that owning compute at scale changes what's possible for medicine discovery, development, and delivery.
Seeing the Full Picture: How Sensor Fusion is Transforming Operations Across Industries
Discover how WWT's sensor fusion architecture — combining camera-based computer vision, LiDAR and IoT data — is delivering more accurate, resilient and actionable operational intelligence across industries, from manufacturing and logistics to retail and healthcare.
Global Pharmaceutical Company Accelerates Comparison of SASE Solutions
WWT helped the company execute a proof of concept as it prepares for a divestiture.
Navigating the Rapids: Insights on How WWT Drives Healthcare Innovation
The rapidly evolving landscape of healthcare and life sciences presents both unprecedented opportunities and challenges. This article shares key insights on how WWT is uniquely positioned to help healthcare organizations stay ahead of these challenges through innovative solutions and strategic partnerships.
Matching the 'Clock Speed of AI' with Softchoice CEO Andrew Caprara
Softchoice CEO Andrew Caprara explains why AI transformation must be CEO-led, and strips the hype away from AI agents, describing them as simply data, a set of rules and connections into existing systems. He argues small and mid-market companies are often better positioned than large enterprises to move quickly, since they carry less legacy technical debt and fewer layers of decision-making, but only if they start with one workflow rather than attempting an enterprise-wide transformation.
LLM Powered Clinical Trial Matcher
The recruitment of patients for clinical trials presents significant challenges for pharmaceutical companies, often delaying drug development, increasing cost, and lead to study failure. This lab explores how AI applied to anonymized health records enables efficient trial matching—at single, bulk, and multi-trial levels—reducing time, improving accuracy, and enhancing access for researchers, providers, and patients.
Top-tier Pharma Achieves OT Cybersecurity Across Plants Globally
WWT deployed a global OT cybersecurity solution for a top-tier pharmaceutical company. Our efforts achieved visibility of IT and operational technology (OT) assets, plus vulnerability detection across plants globally.
Optimizing Cloud Strategies for High-Performance Computing in Life Sciences
The life sciences industry is undergoing a significant shift, with 33 percent of investment dollars expected to go toward AI by 2025. This surge in AI adoption is driving an increased need for high-performance computing (HPC) to power genomics, proteomics and other data-intensive research. In this episode of WWT Experts, Chief Healthcare and Global Life Sciences Advisor Dr. Sanaz Cordes and Technical Solutions Architect Derrick Monahan discuss how organizations can leverage cloud for HPC based on key business and technical considerations.
Agentic AI in Life Sciences Manufacturing
Every life sciences application is quietly shipping AI agents inside routine upgrades; no strategy meeting required. This replays the ERP sprawl mistake, only faster and quieter, and this time touching GxP decisions regulators expect to trace. We predict that by 2027, it will be everywhere. The fix is deciding, now, who owns the architecture and who owns the agent.
Test Automation for a Major Pharmaceutical Company to Maintain Federal Compliance
WWT and a global pharmaceutical company worked together to create a suite of tests that drove compliance with FDA Part 11 in its digital signing processes.